GnRH fragment: first five building blocks of the reproductive hormone
A natural breakdown piece of GnRH, the brain's master reproductive hormone, that has its own separate effects in the body; used only as a laboratory research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
LHRH (1–5) is the first five amino acids of gonadotropin-releasing hormone (GnRH), the master reproductive signaling peptide produced by the hypothalamus. While full-length GnRH (a 10-residue peptide) is well-characterized as a hormone that drives pituitary production of LH and FSH, this N-terminal fragment has attracted research interest as a biologically active breakdown product with its own distinct signaling activity — one that does not simply reproduce what the parent hormone does.
The stored sequence, QHWSY, represents residues 1–5 in standard single-letter amino acid code. In intact GnRH the first residue is actually pyroglutamate (pGlu), a cyclized form of glutamine that forms spontaneously during or after translation; the Q in the stored sequence is the glutamine precursor before that cyclization occurs.
What it does
Full-length GnRH, from which this fragment derives, regulates the reproductive axis by stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive testosterone and estrogen production in the gonads (Tukun and colleagues, 2017). LHRH (1–5) does not replicate this function in the same way. Instead, research has shown that the fragment acts through a different receptor — an orphan G protein-coupled receptor distinct from the classical GnRH receptor — and that this interaction activates epidermal growth factor receptor (EGFR) signaling in human endometrial cells (Cho-Clark and colleagues, 2014). The fragment is therefore a research tool for understanding what the GnRH axis does beyond its canonical reproductive hormone role.
GnRH and its signaling components also interact with immune pathways. Quintanar and colleagues (2013) reviewed the connections between hypothalamic neurohormones, including GnRH-family peptides, and immune system function — a context in which GnRH fragments have been studied as potential modulators.
Evidence
- Human: No clinical trials involving LHRH (1–5) as an independent compound are on record. Evidence is entirely preclinical and mechanistic.
- Animal: Not established for this specific fragment in isolation.
- In vitro: Cho-Clark and colleagues (2014) demonstrated that GnRH-(1–5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor, establishing cell-line evidence for receptor engagement and downstream signaling independent of the classical GnRH receptor.
Mechanism
Full-length GnRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) binds the GnRH receptor (GnRHR) on pituitary gonadotroph cells and triggers LH and FSH secretion. The receptor and its intrinsic and regulated transcriptional control in gonadotrophs are well characterized (Janjic and colleagues, 2017; Sperduti and colleagues, 2019). GnRHR signaling involves Gq/phospholipase C coupling, and commercial GnRH antagonists — which differ from one another by only one or two residues — show differential modulation of these downstream pathways (Sperduti and colleagues, 2019).
LHRH (1–5), however, does not engage the canonical GnRHR with the same affinity as the intact decapeptide, because the C-terminal residues of GnRH (Gly-Leu-Arg-Pro-Gly-NH2) are critical for GnRHR binding. Instead, Cho-Clark and colleagues (2014) identified that the fragment signals through a separate orphan GPCR in endometrial tissue, leading to EGFR transactivation — a pathway used by several peptide fragments to influence cell proliferation and survival independently of the parent hormone's primary receptor. The biological role of this pathway in vivo, and whether it operates in tissues beyond the endometrium, remains an open question.
GnRH-related peptides and receptors are also expressed in mammalian tissues beyond the pituitary. Desaulniers and colleagues (2017) reviewed the expression and roles of GnRH2 and its receptor in mammals, documenting that GnRH signaling extends into brain regions, immune cells, and reproductive organs — a broader context in which the activity of proteolytic fragments like LHRH (1–5) may be physiologically relevant.
Open questions
- Whether the orphan GPCR through which GnRH-(1–5) signals has been formally identified and deorphanized
- Whether EGFR transactivation by the fragment has been replicated in cell types beyond the Ishikawa endometrial line
- Whether endogenous generation of LHRH (1–5) from GnRH proteolysis occurs at physiologically meaningful levels in vivo
- Whether the fragment's activity in endometrial tissue has implications for reproductive-tract biology or endometrial pathology
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the computer model be pointing scientists at the wrong target?
If the peptide turns out to work through GPR101 rather than the classical GnRH receptor, drug developers would be researching the wrong protein. Getting this right early could save years of effort and point researchers toward the receptor that actually matters.
Does the peptide become more potent after a small spontaneous chemical change that happens inside the body?
If this chemical conversion does boost potency, then lab studies using the raw synthetic form could be underestimating what the peptide actually does in a living body. A stabilized version of the converted form could become a better research tool or drug candidate for conditions involving this signaling pathway.
Could two specific changes to QHWSY make it last long enough in the body to be therapeutically useful?
Short peptides are typically broken down quickly in the bloodstream, limiting their use as drugs. If these two modifications do improve stability while keeping the peptide active at its target, that would give medicinal chemists a practical starting point for developing GPR101-targeting medicines.
Could a fragment of a fertility hormone also influence how the brain regulates eating and energy use?
If QHWSY does act on appetite-related brain circuits, it could help explain why nutrition and reproductive health are so tightly connected in humans and animals. That connection, if confirmed, might eventually point toward new ways to address eating disorders or metabolic conditions tied to hormonal imbalance.
Does QHWSY hit only the newer, less-understood receptor and avoid the well-known ones?
Drugs that hit only one receptor tend to have fewer side effects than ones that hit several. If QHWSY is naturally selective for GPR101, it would be a rare ready-made probe for studying a receptor that science still knows very little about, and a potential starting point for cleaner, more targeted therapies.
Is just one building block in this five-part peptide the key that unlocks the receptor?
If tryptophan at position 3 turns out to be the only piece that truly matters, chemists could design much simpler and more stable molecules built around it. That would make developing a drug far cheaper and faster than optimizing the full peptide.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.962273120880127 | boltz-2 |
| ranking score | 0.8311101794242859 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10731,
sequence = {QHWSY},
target = {gnrhr},
author = {peptidemodel},
year = {2026},
status = {computed}
}